All In Biotech

Drug Trial Radar · NCT05801094

A Phase I Study of QL1604 for Advanced Solid Tumors

A Phase I Clinical Study to Evaluate Safety、 Tolerability, and Pharmacokinetics of QL1604 for the Treatment of Advanced Solid Tumors - A Phase Ic Preliminary Efficacy Expansion Study

Last checked: Nov 19, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

71

Actual

Start

Jul 20, 2020

Primary completion

Apr 15, 2023

Study completion Dec 15, 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

Conditions

  • Advanced Solid Tumor

Interventions

  • QL1604Drug

    QL1604 3 mg/kg Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affliated Hospital of Nanchang University

    Nanchang, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.